Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-23
2011-08-23
Reddig, Peter J (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387700, C530S388100, C530S388800, C530S391100, C530S391300
Reexamination Certificate
active
08003761
ABSTRACT:
The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
REFERENCES:
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5354847 (1994-10-01), Liu et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5552291 (1996-09-01), Yoshida et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 6180357 (2001-01-01), Young et al.
patent: 2003/0105000 (2003-06-01), Pero et al.
patent: 2004/0180002 (2004-09-01), Young et al.
patent: 2004/0197328 (2004-10-01), Young et al.
patent: 2004/0258693 (2004-12-01), Young et al.
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: 2043951 (1991-12-01), None
patent: 0234122 (1987-09-01), None
patent: 0424107 (1991-04-01), None
patent: 0460607 (1991-12-01), None
Janeway et al. (Immunobiology 5, 2001, p. 100-101).
Rudikoff et al (Proc Natl Acad Sci USA 1982 79: 1979-1983).
Gussow et al. (1991, Methods in Enzymology 203:99-121).
MacCallum et al. (J. Mol. Biol. 1996 262, 732-745).
Wu et al. (J. Mol. Biol. (1999) 294, 151-162).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12: 320).
Drexler et al (Leukemia and Lymphoma, 1993, 9:1-25).
Zellner et al (Clin. Can. Res., 1998, 4:1797-1802).
Embleton et al (Immunol Ser, 1984, 23:181-207).
Zips et al (In Vivo, 2005, 19:1-7).
Gura (Science, 1997, 278:1041-1042).
Kaiser (Science, 2006, 313: 1370) teaches.
Stites et al (Medical Immunology, 9th Ed, Appleton and Lange, Stamford, 1997, p. 250-251).
Schreier et al. (Nucl Acids Res. 14:2381-2389 (1986)).
Straub P. et al. (1993, J. Biol. Chem. 268(29): 21,997-22,003).
Kouklis PD et al. (1993 J Cell Science, 106(pt 3): 919-928).
Kohler et al., Nature, 256:495-497 (1975).
Examination report dated Jun. 17, 2008 for U.S. Appl. No. 11/774,293.
Examination report dated Mar. 20, 2009 for U.S. Appl. No. 11/777,551.
Examination report dated Apr. 10, 2009 for U.S. Appl. No. 11/774,293.
Examination report dated Apr. 22, 2009 for U.S. Appl. No. 11/879,676.
Examination report dated Jun. 4, 2009 for U.S. Appl. No. 11/880,619.
Examination report dated Jun. 12, 2009 for U.S. Appl. No. 12/284,137.
Examination report dated Mar. 11, 2010 for U.S. Appl. No. 12/102,983.
Examination report dated Apr. 21, 2010 for U.S. Appl. No. 11/807,887.
Examination report dated May 4, 2010 for U.S. Appl. No. 11/807,681.
Examination report dated May 6, 2010 for U.S. Appl. No. 11/364,013.
Examination report dated May 24, 2010 for U.S. Appl. No. 12/217,279.
Examination report dated May 28, 2010 for U.S. Appl. No. 11/938,841.
Examination report dated May 3, 2010 for U.S. Appl. No. 12/357,031.
Examination report dated May 3, 2010 for U.S. Appl. No. 12/356,980.
Examination report dated Jan. 13, 2010 for U.S. Appl. No. 12/017,827.
Examination report dated Jan. 14, 2010 for U.S. Appl. No. 12/114,090.
Examination report dated Jan. 14, 2010 for U.S. Appl. No. 11/807,887.
Examination report dated Feb. 19, 2010 for U.S. Appl. No. 12/055,014.
Examination report dated Feb. 25, 2010 for U.S. Appl. No. 11/938,832.
Examination report dated Apr. 5, 2010 for U.S. Appl. No. 12/017,886.
Examination report dated Apr. 8, 2010 for U.S. Appl. No. 11/786,165.
Examination report dated Jun. 16, 2009 for U.S. Appl. No. 12/055,014.
Examination report dated Apr. 12, 2009 for U.S. Appl. No. 11/938,846.
Examination report dated Jul. 1, 2009 for U.S. Appl. No. 11/938,841.
Examination report dated Jul. 15, 2009 for U.S. Appl. No. 12/017,827.
Examination report dated Jul. 24, 2009 for U.S. Appl. No. 11/975,896.
Examination report dated Jul. 27, 2009 for U.S. Appl. No. 12/102,662.
Examination report dated Jul. 29, 2009 for U.S. Appl. No. 11/807,887.
Examination report dated Jul. 30, 2009 for U.S. Appl. No. 11/807,837.
Examination report dated Aug. 10, 2009 for U.S. Appl. No. 12/017,855.
Examination report dated Aug. 13, 2009 for U.S. Appl. No. 11/807,681.
Examination report dated Oct. 13, 2009 for U.S. Appl. No. 11/786,165.
Examination report dated Oct. 16, 2009 for U.S. Appl. No. 12/102,953.
Examination report dated Nov. 10, 2009 for U.S. Appl. No. 12/172,645.
Examination report dated Nov. 19, 2009 for U.S. Appl. No. 11/938,846.
Examination report dated Nov. 30, 2009 for U.S. Appl. No. 12/220,362.
Examination report dated Dec. 1, 2008 for U.S. Appl. No. 11/786,165.
Examination report dated Dec. 10, 2009 for U.S. Appl. No. 12/229,187.
Examination report dated Dec. 14, 2009 for U.S. Appl. No. 12/229,203.
Examination report dated Oct. 15, 2009 for U.S. Appl. No. 12/313,298.
Examination report dated Jul. 17, 2009 for U.S. Appl. No. 11/938,832.
Examination report dated Jun. 24, 2010 for U.S. Appl. No. 12/017,855.
Examination report dated Jul. 21, 2010 for U.S. Appl. No. 12/229,187.
Examination report dated Jul. 23, 2010 for U.S. Appl. No. 12/229,203.
Examination report dated Jul. 29, 2010 for U.S. Appl. No. 12/378,332.
Examination report dated Aug. 25, 2010 for U.S. Appl. No. 12/313,298.
International Search Report dated May 14, 2008 for PCT/CA2008/000151.
International Preliminary Examination Report/Written Opinion dated Jul. 28, 2009 for PCT/CA2008/000151.
Azuma A. et al.: 'Augmented lung adenocarcinoma cytotoxicity by the combination of genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins' vol. 42, 1995, pp. 202-208, XP000941182.
Anonymous, “Product description ATCC No. CRL-1435 (PC-3),” 2010, pp. 1-2 Retrieved from the Internet: URL:http://www.atcc.org/ATCCAdvanced CatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=CRL-1435&Template=cellBiology[retrieved on Oct. 22, 2010].
Anonymous, “Product description ATCC No. CRL-1687 (BxPC-3),” 2010, pp. 1-2 Retrieved from the Internet: URL:http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=CRL-1687&Template=cellBiology[retrieved on Oct. 22, 2010].
Anonymous, “Product description ATCC No. CRL-5800 (NCI-H23),” 2010, pp. 1-2 Retrieved from the Internet: URL:http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=CRL-5800&Template=cellBiology[retrieved on Oct. 22, 2010].
Anonymous, “Product description ATCC No. HTB-161 (NIH:OVAR-3),” 2010, pp. 1-2 Retrieved from the Internet: URL:http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=HTB-161&Template=cellBiology[retrieved on Oct. 22, 2010].
Anonymous, “Product description ATCC No. HTB-26 (MDA-MB-231),” 2010, pp. 1-2 Retrieved from the Internet: URL:http://www.atcc.org/ATCCAdvanced CatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNum=HTB-26&Template=cellBiology[retrieved on Oct. 22, 2010].
European Search Report issued in 08706298.0 on Dec. 7, 2010.
Hellstrom et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas,” Proceedings of the National Academy of Sciences of the United States of America, 83(18):7059-7063 (1986).
O'Donnell et al., “L6 monoclonal antibody binds prostate cancer,” Prostate, Wiley-Liss, New York, 37(2):0270-4137.
Vardi et al., “Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies,” Canc
Findlay Helen P.
Hahn Susan E.
Popp Lisa A.
Young David S. F.
Fish & Richardson P.C.
Hoffmann-La Roche Inc.
Reddig Peter J
LandOfFree
Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2770884